Establishing the Role of Tigecycline in an era of Antimicrobial Resistance

Jason J. Schafer; Debra A. Goff


Expert Rev Anti Infect Ther. 2008;6(5):557-567. 

In This Article

Five-year View

In an era of increasing antimicrobial resistance, there is a growing need for new antimicrobial agents with novel mechanisms of action. Tigecycline is an agent derived from tetracycline antimicrobials with a broad spectrum of activity, including some drug-resistant pathogens. In addition to clinical trial data, early off-label and in vitro experiences indicate a potential role for tigecycline in the management of certain infections with drug-resistant isolates. This is especially noteworthy given the continuing emergence of resistant bacteria for which there are limited antimicrobial options available. Emergence of resistance to tigecycline is currently uncommon but has been encountered clinically. Further studies are needed to determine the ultimate role of tigecycline for treating serious infections with drug-resistant pathogens.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.